We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Brush Biopsy Test Detects Oral Cancer without Surgery

By LabMedica International staff writers
Posted on 18 Jan 2024
Image: The cancer detection kit requires less than a minute of gentle brushing to collect a sample (Photo courtesy of Lucia Adami)
Image: The cancer detection kit requires less than a minute of gentle brushing to collect a sample (Photo courtesy of Lucia Adami)

Oral squamous cell carcinoma, the most common type of oral cancer and globally the ninth most prevalent cancer, currently relies on surgical biopsies for diagnosis. This additional referral step poses the risk of losing patients who may not return for follow-up until the cancer has progressed to advanced, more challenging stages. Additionally, surgical biopsies can be problematic as they often collect a mix of cell types, complicating the analysis, and creating the risk of spreading cancerous cells to other parts of the mouth. General blood tests looking for cancer's genetic signals also have limitations, as they do not specify the tumor’s location, preventing quick initiation of treatment after detection. Now, a new test that allows dentists to screen for oral squamous cell carcinoma with a simple brush could early detection of oral cancer without surgery.

The diagnostic kit, created by researchers at the University of Illinois Chicago (Urbana, IL, USA), employs a small brush to gather cells from potential cancerous lesions in the mouth. It operates by detecting tiny segments of genetic material, known as microRNA, which regulate gene expression. Studies conducted by the researchers found a unique expression signature of 40 microRNA sequences that can accurately differentiate between a tumor and normal tissue with more than 90% accuracy. Significantly, their test also successfully works with epithelial cells, the outermost layer in the patient’s mouth. These cells can be quickly and painlessly collected in under a minute by a dentist or nurse using gentle brushing. After collection, the brush is placed in a solution tube and sent to a lab for microRNA analysis, with results being available within days using the current test version.

The brush biopsy test offers several advantages, including specific targeting of the tissue site. The researchers anticipate that this new test will simplify screening, especially in populations that lack regular dental care or are more prone to oral squamous cell carcinoma. For instance, Black men, who experience significantly lower survival rates with this disease compared to other racial groups, could benefit greatly. The potential for using this technology in non-clinical settings opens up opportunities for earlier cancer detection in high-risk groups. Additionally, this approach could eventually help diagnose other oral diseases, each identified by unique microRNA signatures.

“We were the first to observe that brush biopsy samples actually work quite well when you use microRNA,” said Guy Adami of the UIC College of Dentistry. “All you need is a good light and the brushes.”

“There are 600 different diseases that occur in the mouth, and a number of these have already been characterized with microRNAs,” added Dr. Joel Schwartz of the UIC College of Dentistry. “We could use the same approach and really have a profound impact on these kinds of disease.”

Related Links:
University of Illinois Chicago

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more